Published on: August 11, 2017 at 09:30PM
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin; Drug: Empagliflozin; Drug: Dapagliflozin; Drug: Dipeptidyl Peptidase-4 Inhibitor (DPP-4); Drug: Glucagon-Like Peptide-1 Agonist (GLP-1); Drug: Thiazolidinedione (TZD); Drug: Sulfonylureas; Drug: Insulin
Sponsor: Janssen Research & Development, LLC
Active, not recruiting – verified August 2017
https://clinicaltrials.gov/ct2/show/NCT03249506?term=diabetes&rcv_d=14&show_rss=Y